<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/91C7FC2B-28F1-4D8A-B83F-1D2C77CDD0B8"><gtr:id>91C7FC2B-28F1-4D8A-B83F-1D2C77CDD0B8</gtr:id><gtr:firstName>Jean</gtr:firstName><gtr:surname>Rodgers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/762ACFA0-8B24-4216-88F7-35B28948C9A3"><gtr:id>762ACFA0-8B24-4216-88F7-35B28948C9A3</gtr:id><gtr:firstName>Barrie</gtr:firstName><gtr:surname>Condon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7CBDECC2-D2B3-4BA8-8770-A921721BA5CB"><gtr:id>7CBDECC2-D2B3-4BA8-8770-A921721BA5CB</gtr:id><gtr:firstName>PETER</gtr:firstName><gtr:otherNames>GRAHAM</gtr:otherNames><gtr:surname>KENNEDY</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601059"><gtr:id>BEBF5EF0-F14F-4419-9011-70C6E381CC71</gtr:id><gtr:title>Combination chemotherapy of Human African trypanosomiasis: the potential of drug synergism and the blood-brain barrier</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601059</gtr:grantReference><gtr:abstractText>Our goal is to gain a greater understanding and improve treatment of Human African Trypanosomiasis (HAT), also known as sleeping sickness. HAT is a major cause of suffering and death in 36 countries throughout sub-Saharan Africa and is always fatal if untreated. 
The disease is caused by parasites called trypanosomes that are spread by the bite of the tsetse fly. The East African form of HAT is caused by T.b.rhodesiense and the West African form by T.b.gambiense. In early-stage disease the parasites invade the bloodstream and major organs, and at the late-stage the central nervous system (CNS) is invaded. For the parasites to enter the CNS they must cross a structure called the ?blood-brain barrier? (BBB). 
We use a mouse model that closely mirrors the human disease, characterised by the development of a severe inflammatory reaction in the brain. Melarsoprol, the drug most frequently used for CNS infection, kills 5% of all patients who receive it due to brain inflammation. Because of this problem new methods of treating CNS disease are urgently needed. We will use reduced dosages of melarsoprol combined with other drugs to treat trypanosome-infected mice. MRI , a powerful method of visualising the BBB, will be used to monitor BBB function . This project will highlight which drug combinations are the most effective.</gtr:abstractText><gtr:technicalSummary>Human African Trypanosomiasis (HAT), or sleeping sickness, caused by protozoan parasites of the Trypanosoma genus, is a major cause of human mortality and morbidity in 36 countries in sub-Saharan Africa, with an estimated annual prevalence of 300-500,000 cases and a mortality rate of 60-100,000 per year. HAT is invariably fatal if untreated. The most used drug for late-stage disease in which the parasites invade the CNS, is the trivalent arsenical, melarsoprol. No alternative to melarsoprol is available for T.b.rhodesiense disease,and there are no new CNS drugs for HAT on the horizon. Unfortunately melarsoprol kills 5% of patients who receive it through the development of a severe post-treatment reactive encephalopathy (PTRE). The PTRE occurs in 10% of patients with a mortality rate of 50%. One approach to prevent the PTRE would be to minimise the dosage of melarsoprol administered. This project will use an established model of late-stage HAT, that closely mirrors the neuropathological features of the human CNS disease, to determine the effects of melarsoprol in combination with other trypanocidal drugs on; (i) the clinical and neuropathological phenotype of experimental HAT, (ii) the degree of breakdown of BBB function as assessed by 7 Tesla Magnetic Resonance Imaging (MRI), (iii) the drug availability within the CNS as measured by reverse-phased HPLC analyses and (iv) the changes in brain cytokines that these drug combinations induce. The core hypothesis of this proposal is that melarsoprol improves the penetration of trypanocidal drugs into the CNS by reducing the integrity of the BBB thereby increasing treatment efficacy. The hypothesis predicts that melarsoprol, when given in combination with secondary trypanocidal agents, will reduce function of the BBB leading to increased concentration of the trypanocidal drugs and trypanocidal activity within the CNS. The project will therefore determine (i) the lowest dose of melarsoprol that will lead to reduced BBB function and improved treatment efficacy, (ii) how melarsoprol instigates the BBB changes e.g. whether it is a direct effect, whether it?s trypanocidal properties are important, or whether the BBB changes are secondary to changes in brain cytokine expression,(iii) the tempo of clearing of the parasites from the CNS following combination chemotherapy and (iv) whether complexed melarsoprol therapy is effective and non-toxic. The results of this study will enhance knowledge of HAT chemotherapy and CNS drug penetration. The findings will facilitate a rational approach to the design of novel combination chemotherapy strategies for improved safety and efficacy in HAT</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>478968</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Infection, Immunity and Inflammation</gtr:department><gtr:description>In vivo imaging models of African trypanosomiasis</gtr:description><gtr:id>66482F64-EBA5-4617-98F8-9B62C9060CA7</gtr:id><gtr:impact>Successful grant application funded by Bill and Melinda Gates Foundation</gtr:impact><gtr:outcomeId>C7F9A87D060-2</gtr:outcomeId><gtr:partnerContribution>Provision of imaging tools and methodologiesProvision of imaging tools and methodologiesProvision of microsurgery methodologies</gtr:partnerContribution><gtr:piContribution>Performance of MRI to validate CNS neuroinflammatory profile as a result of infection with genetically altered trypanosomes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Infectious and Tropical Diseases</gtr:department><gtr:description>In vivo imaging models of African trypanosomiasis</gtr:description><gtr:id>F01AF943-6836-430D-A4AB-F88561092588</gtr:id><gtr:impact>Successful grant application funded by Bill and Melinda Gates Foundation</gtr:impact><gtr:outcomeId>C7F9A87D060-1</gtr:outcomeId><gtr:partnerContribution>Provision of imaging tools and methodologiesProvision of imaging tools and methodologiesProvision of microsurgery methodologies</gtr:partnerContribution><gtr:piContribution>Performance of MRI to validate CNS neuroinflammatory profile as a result of infection with genetically altered trypanosomes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmidex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>In vivo imaging models of African trypanosomiasis</gtr:description><gtr:id>92A12EB3-7232-4532-8FAF-0C8838936A82</gtr:id><gtr:impact>Successful grant application funded by Bill and Melinda Gates Foundation</gtr:impact><gtr:outcomeId>C7F9A87D060-3</gtr:outcomeId><gtr:partnerContribution>Provision of imaging tools and methodologiesProvision of imaging tools and methodologiesProvision of microsurgery methodologies</gtr:partnerContribution><gtr:piContribution>Performance of MRI to validate CNS neuroinflammatory profile as a result of infection with genetically altered trypanosomes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited Lecture Grand Rounds</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>66785CFB-3401-49B5-8023-AE3B12758FC0</gtr:id><gtr:impact>This was followed by extensive questioning demonstrating the interest of the audience.

Very positive feedback from talk organiser</gtr:impact><gtr:outcomeId>c87FJtYwvff</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A83846B1-32A2-495B-918E-600227895F32</gtr:id><gtr:impact>The whole centre for infection at Columbia University attended with questions and discussion afterwards. Title 'The problem of human African trypanosomiasis (Sleeping Sickness) in Sub-Saharan Africa'

Excellent feedback from Centre afterwards</gtr:impact><gtr:outcomeId>mxYaBibeDMA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dana Centre for the Brain, Science Museum, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9512E02A-5A88-4D08-866B-77BB16D39703</gtr:id><gtr:impact>Large audience attended and received favourable feedback fro organiser

Significantly increased public awareness of sleeping sickness in Africa</gtr:impact><gtr:outcomeId>SfQn1d2H7Kc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Lecture - Melarsoprol</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0EE2D0B7-8988-4B7F-B149-ADCB797913B8</gtr:id><gtr:impact>Presentation on Human African trypanosomiasis to clinical pharmacologists at Johns Hopkins University

Very positive feedback especially regarding new oral melarsoprol drug therapy for trypanosomiasis</gtr:impact><gtr:outcomeId>XapCVmvZfGi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>358628</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Project Grant (Defining the role of the chemokine CXCL10 in determining traversal of trypanosomes across the blood-brain barrier in experimental and human trypanosomiasis.)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>089992/z/09/z</gtr:fundingRef><gtr:id>19C35ED2-3FEF-40C7-A6E5-9F7A4EF601E7</gtr:id><gtr:outcomeId>VPiT22Q3jgx0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1750000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gates Project Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>D0D0EECB-CF6E-4B79-AC33-EF0EBCE64E7D</gtr:id><gtr:outcomeId>9B71444939D0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>363380</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Project Grant</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>094691/z/10/z</gtr:fundingRef><gtr:id>80ED92E1-2830-4DDF-A803-F970EF0C4C47</gtr:id><gtr:outcomeId>ALeYwoAsqBb0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>EMA has designated this novel compound as an orphan drug for treatment of human trypanosome infections (Oct 2012). Currently seeking funding for phase II trial. Pharmaceutical partner has been identified and trial design in progress. Ugandan ministry of health has agreed to be trial sponsor.</gtr:description><gtr:id>3FFCC29F-E5E4-460C-835E-E78EFD2F02B8</gtr:id><gtr:impact>This drug offers the possibility of orally available, effective and less toxic treatment for CNS-stage T.b.rhodesiense disease</gtr:impact><gtr:outcomeId>rpLNjsASff7</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Complexed melarsoprol</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Oral complexed melarsoprol by FDA in addition to EMA. Currently seeking funding for phase II clinical trial.</gtr:description><gtr:id>758198C9-D924-4629-9CE4-B41252A01072</gtr:id><gtr:impact>Many potential impacts following successful pre-clinical assessment</gtr:impact><gtr:outcomeId>f4F5Uw3DpF2</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Complexed Melarsoprol FDA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>12069950-87B5-4D33-885A-78FBF3A0694A</gtr:id><gtr:title>Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13ee9af6e20e33ac1cb4f66f44d39bb0"><gtr:id>13ee9af6e20e33ac1cb4f66f44d39bb0</gtr:id><gtr:otherNames>Rodgers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>XCF4XaHmBVn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F1A6B7-9499-4212-8A77-8A5C6D46B4A8</gtr:id><gtr:title>The continuing problem of human African trypanosomiasis (sleeping sickness).</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/822dbffe60501f8c0e0e5efd59cbbf26"><gtr:id>822dbffe60501f8c0e0e5efd59cbbf26</gtr:id><gtr:otherNames>Kennedy PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>5BCD96CE240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C5D6B5D-D1D1-49AB-B3C6-1C453227EE62</gtr:id><gtr:title>Trypanosomiasis and the brain.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13ee9af6e20e33ac1cb4f66f44d39bb0"><gtr:id>13ee9af6e20e33ac1cb4f66f44d39bb0</gtr:id><gtr:otherNames>Rodgers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn><gtr:outcomeId>UQB99CAsBZa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F8AC17A-0105-4BE5-9D5D-ACB9A4830C95</gtr:id><gtr:title>Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13ee9af6e20e33ac1cb4f66f44d39bb0"><gtr:id>13ee9af6e20e33ac1cb4f66f44d39bb0</gtr:id><gtr:otherNames>Rodgers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>LatZ3bicp9T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56774BD1-D5B5-438B-A797-665B3BAB3F3C</gtr:id><gtr:title>Human African trypanosomiasis, chemotherapy and CNS disease.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13ee9af6e20e33ac1cb4f66f44d39bb0"><gtr:id>13ee9af6e20e33ac1cb4f66f44d39bb0</gtr:id><gtr:otherNames>Rodgers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>YAyZ82ckR4i</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601059</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>